BMO Capital Initiates Coverage on 7 Biotech Stocks: Outperform Ratings for ALNY, ASND, BMRN & More
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
/ 3 items
#BCAX↓
BofA Calls Bicara Therapeutics a Buy – Sees Ficerafusp Alfa as Transformative
BofA starts coverage on Bicara Therapeutics with a Buy rating and $35 price target. Ficerafusp alfa shows strong potential in head and neck cancer with clear differentiation over standard care.
FDA Grants Breakthrough Status to Promising Head and Neck Cancer Treatment
Bicara Therapeutics' ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits.